Patents by Inventor Saswata Lahiri
Saswata Lahiri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295077Abstract: The present invention relates to an improved process for the preparation of a compound of Formula (1), The invention also provides improved processes for the preparation of intermediates used in the synthesis of Formula (1). The compound of Formula (1) is used in the synthesis of Semaglutide.Type: ApplicationFiled: April 9, 2021Publication date: September 21, 2023Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Maneesh Kumar PANDEY, Sonu Prasad SHUKLA, Sachin NAIN, Sandeep SANDEEP, Sridhar MALE, Sarbjot Singh SOKHI, Govind SINGH, Saswata LAHIRI, Walter CABRI
-
Patent number: 11739057Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.Type: GrantFiled: June 3, 2021Date of Patent: August 29, 2023Assignee: FRESENIUS KABI ONCOLOGY LTD.Inventors: Sridhar Reddy Male, Saurabh Upadhyay, Suneel Kumar Sharma, Hrishikesh Acharya, Govind Singh, Saswata Lahiri, Walter Cabri
-
Publication number: 20230174444Abstract: The present provides a simple, convenient and time-efficient process for the preparation of propofol. Particularly, the present invention provides an improved process for the preparation of propofol using a heterocyclic base for the decarboxylation reaction. The present invention provides a time-efficient process for the preparation of propofol with high yield and purity.Type: ApplicationFiled: March 25, 2021Publication date: June 8, 2023Applicant: FRESENIUS KABI ONCOLOGY LTD.Inventors: Ashwani Kumar SHARMA, Manish PANDEY, Abhishek GIRI, Sarbjot Singh SOKHI, Govind SINGH, Saswata LAHIRI, Walter CABRI
-
Patent number: 11667654Abstract: The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PG1 may be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC.Type: GrantFiled: February 19, 2018Date of Patent: June 6, 2023Assignee: Fresenius Kabi Oncology Ltd.Inventors: Maneesh Kumar Pandey, Raj Narayan Tiwari, Sonu Shukla, Sarbjot Singh Sokhi, Govind Singh, Saswata Lahiri, Walter Cabri
-
Patent number: 11465999Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.Type: GrantFiled: August 16, 2021Date of Patent: October 11, 2022Assignee: FRESENIUS KABI ONCOLOGY LTD.Inventors: Vinod Singh Tomar, Abul Azim, Nitin Gupta, Saswata Lahiri, Walter Cabri
-
Patent number: 11440912Abstract: The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer.Type: GrantFiled: October 26, 2018Date of Patent: September 13, 2022Assignee: FRESENIUS KABI ONCOLOGY LTDInventors: Sarbjot Singh Sokhi, Govind Singh, Saswata Lahiri, Maneesh Kumar Pandey, Raj Narayan Tiwari, Sonu Shukla, Sachin Musmade, Heena Dua, Walter Cabri
-
Patent number: 11390612Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.Type: GrantFiled: October 1, 2020Date of Patent: July 19, 2022Assignee: Fresenius Kabi Oncology Ltd.Inventors: Walter Cabri, Saswata Lahiri, Bhuwan Bhaskar Mishra, Abul Azim, Nilendu Panda, Poli Reddy Bhavanam, Krishanu Ray, Nikunj Kachhadia, Kumber Singh
-
Publication number: 20210371410Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.Type: ApplicationFiled: August 16, 2021Publication date: December 2, 2021Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Vinod Singh TOMAR, Abul AZIM, Nitin GUPTA, Saswata LAHIRI, Walter CABRI
-
Publication number: 20210292276Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.Type: ApplicationFiled: June 3, 2021Publication date: September 23, 2021Applicant: FRESENIUS KABI ONCOLOGY LTD.Inventors: Sridhar Reddy MALE, Saurabh UPADHYAY, Suneel Kumar SHARMA, Hrishikesh ACHARYA, Govind SINGH, Saswata LAHIRI, Walter CABRI
-
Patent number: 11098037Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.Type: GrantFiled: July 4, 2018Date of Patent: August 24, 2021Assignee: Fresenius Kabi Oncology Ltd.Inventors: Vinod Singh Tomar, Abul Azim, Nitin Gupta, Saswata Lahiri, Walter Cabri
-
Patent number: 11078231Abstract: The present invention relates to a process for the purification of compound of formula II, wherein X may be independently selected from trifluoroacetic acid, hydrochloric acid, hydrobromic acid, p-toluene sulfonic acid and phosphoric acid; its isolation as solid and use for the preparation of carfilzomib.Type: GrantFiled: September 13, 2017Date of Patent: August 3, 2021Assignee: FRESENIUS KABI ONCOLOGY LTDInventors: Walter Cabri, Saswata Lahiri, Govind Singh, Sarbjot Singh Sokhi, Maneesh Kumar Pandey, Raj Narayan Tiwari, Sonu Prasad Shukla
-
Patent number: 11059777Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.Type: GrantFiled: July 25, 2017Date of Patent: July 13, 2021Assignee: Fresenius Kabi Oncology Ltd.Inventors: Sridhar Reddy Male, Saurabh Upadhyay, Suneel Kumar Sharma, Hrishikesh Acharya, Govind Singh, Saswata Lahiri, Walter Cabri
-
Publication number: 20210024506Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.Type: ApplicationFiled: October 1, 2020Publication date: January 28, 2021Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Walter CABRI, Saswata LAHIRI, Bhuwan Bhaskar MISHRA, Abul AZIM, Nilendu PANDA, Poli Reddy BHAVANAM, Krishanu RAY, Nikunj KACHHADIA, Kumber SINGH
-
Patent number: 10800763Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.Type: GrantFiled: June 10, 2016Date of Patent: October 13, 2020Assignee: Fresenius Kabi Oncology Ltd.Inventors: Walter Cabri, Saswata Lahiri, Bhuwan Bhaskar Mishra, Abul Azim, Nilendu Panda, Poli Reddy Bhavanam, Krishanu Ray, Nikunj Kachhadia, Kumber Singh
-
Publication number: 20200277295Abstract: The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer.Type: ApplicationFiled: October 26, 2018Publication date: September 3, 2020Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Sarbjot Singh SOKHI, Govind SINGH, Saswata LAHIRI, Maneesh Kumar PANDEY, Raj Narayan TIWARI, Sonu SHUKLA, Sachin MUSMADE, Heena DUA, Walter CABRI
-
Publication number: 20200140427Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.Type: ApplicationFiled: July 4, 2018Publication date: May 7, 2020Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Vinod Singh TOMAR, Abul AZIM, Nitin GUPTA, Saswata LAHIRI, Walter CABRI
-
Patent number: 10577433Abstract: The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-?-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.Type: GrantFiled: March 20, 2017Date of Patent: March 3, 2020Assignee: Fresenius Kabi iPSUM S.r.l.Inventors: Walter Cabri, Antonio Ricci, Jacopo Zanon, Saswata Lahiri, Govind Singh, Shivaji Haribhau Shelke, Tapanjyoti Biswal, Nitin Kumar, Madan Singh
-
Publication number: 20200031850Abstract: The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PG1 may be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC.Type: ApplicationFiled: February 19, 2018Publication date: January 30, 2020Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Maneesh Kumar PANDEY, Raj Narayan TIWARI, Sonu SHUKLA, Sarbjot Singh SOKHI, Govind SINGH, Saswata LAHIRI, Walter CABRI
-
Patent number: 10544109Abstract: The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of expensive chemicals, hazardous reagents or tedious purification techniques. Invention also provides novel intermediate useful for preparation of desired compound in high purity.Type: GrantFiled: September 1, 2016Date of Patent: January 28, 2020Assignee: Fresenius Kabi Oncology Ltd.Inventors: Hemant Kumar Singh, Sandeep Kumar, Ghanashyam Madhukar Sonavane, Vishal Handa, Chandan Kumar Gupta, Sunil Sanghani, Potru Sivaiah, Saswata Lahiri, Walter Cabri, Nitin Gupta
-
Publication number: 20190284308Abstract: The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-?-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.Type: ApplicationFiled: March 20, 2017Publication date: September 19, 2019Applicant: FRESENIUS KABI IPSUM S.R.L.Inventors: Walter CABRI, Antonio RICCI, Jacopo ZANON, Saswata LAHIRI, Govind SINGH, Shivaji Haribhau SHELKE, Tapanjyoti BISWAL, Nitin KUMAR, Madan SINGH